Anavex Life Sciences (Nasdaq:AVXL) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AVXL 주식 개요

임상 단계의 바이오 제약 회사인 아나벡스 생명과학은 중추신경계 질환 치료를 위한 치료제 개발에 참여하고 있습니다.

AVXL 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	3/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 99% 에서 거래

수익은 매년 61.13% 증가할 것으로 예상됩니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

지난 1년 동안 주주가 희석되었습니다.

최근 3개월간 주가 변동성

Anavex Life Sciences Corp. 경쟁사

Alector

NasdaqGS:ALEC

US$478.8m

Acelyrin

NasdaqGS:SLRN

US$492.1m

Harpoon Therapeutics

NasdaqCM:HARP

US$492.3m

COMPASS Pathways

NasdaqGS:CMPS

US$465.7m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Anavex Life Sciences
과거 주가
현재 주가	US$5.68
52주 최고치	US$10.45
52주 최저치	US$3.25
베타	0.62
11개월 변경	-5.65%
3개월 변경 사항	38.20%
1년 변경 사항	-13.28%
33년 변화	-68.36%
5년 변화	85.02%
IPO 이후 변화	8,419.83%

최근 뉴스 및 업데이트

Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising

Jul 29

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Jul 17

Recent updates

Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising

Jul 29

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Jul 17

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Apr 01

Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Sep 19

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

May 10

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

Jan 16

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Oct 01

Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia

Sep 19

Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease

Sep 07

Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01

Aug 09

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Jun 17

Anavex: Increasing Shareholder Value Against All Odds

May 31

Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease

Mar 23

We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Mar 03

Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease

Feb 09

Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity

Feb 02

Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers

Jun 21

Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease

Jun 14

Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment

Jun 08

Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease

Apr 28

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Apr 16

Anavex shares up 65% in morning trading continuing hot streak

Feb 04

Anavex Life Sciences Corp.: 2021 Clinical Milestones Support Bullish Momentum

Jan 05

주주 수익률

	AVXL	US Biotechs	US 마켓
7D	0.7%	-2.8%	0.7%
1Y	-13.3%	19.3%	32.3%

수익률 대 산업: AVXL 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: AVXL 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is AVXL's price volatile compared to industry and market?
AVXL volatility
AVXL Average Weekly Movement	10.6%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

안정적인 주가: AVXL 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: AVXL 의 주간 변동성( 10% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2004	40	Chris Missling	www.anavex.com

임상 단계의 바이오 제약 회사인 아나벡스 라이프 사이언스는 중추 신경계 질환 치료를 위한 치료제 개발에 종사하고 있습니다. 주요 제품 후보로는 알츠하이머병과 파킨슨병, 희귀 중증 신경계 단원성 질환인 레트 증후군, 영아 경련, 프래자일 X 증후군, 엔젤만 증후군과 같은 희귀 질환을 포함한 기타 중추 신경계 질환 치료를 위한 ANAVEX 2-73이 있습니다. 또한 정신분열증, 전측두엽 치매, 알츠하이머병 치료를 위한 임상시험 중인 ANAVEX 3-71도 신약 후보물질로 보유하고 있습니다.

Anavex Life Sciences Corp. 기본 사항 요약

Anavex Life Sciences 의 수익과 매출은 시가총액과 어떻게 비교하나요?
AVXL 기본 통계
시가총액	US$481.64m
수익(TTM)	-US$41.53m
수익(TTM)	n/a

0.0x

P/S 비율

-11.6x

P/E 비율

AVXL 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
AVXL 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$41.53m
수익	-US$41.53m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.49
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

AVXL 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

AVXL 주식 개요

보상

위험 분석

Anavex Life Sciences Corp. 경쟁사

NasdaqGS:ALEC

US$478.8m

NasdaqGS:SLRN

US$492.1m

NasdaqCM:HARP

US$492.3m

NasdaqGS:CMPS

US$465.7m

가격 내역 및 성능

최근 뉴스 및 업데이트

Anavex Life Sciences Corp. to Report Q3, 2024 Results on Aug 06, 2024

New minor risk - Share price stability

Forecast breakeven date moved forward to 2025

Anavex Life Sciences Corp. Presents comprehensive results from the Phase IIb/III study of Blarcamesine at Alzheimer's Association Conference

Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Recent updates

Anavex Life Sciences Corp. to Report Q3, 2024 Results on Aug 06, 2024

New minor risk - Share price stability

Forecast breakeven date moved forward to 2025

Anavex Life Sciences Corp. Presents comprehensive results from the Phase IIb/III study of Blarcamesine at Alzheimer's Association Conference

Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Insufficient new directors

Anavex Life Sciences Corp Announces Management Appointments

Anavex Life Sciences Corp., Annual General Meeting, Jun 18, 2024

Anavex Life Sciences Corp. to Report Q2, 2024 Results on May 09, 2024

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

President notifies of intention to sell stock

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®?3-71 in Schizophrenia

Levi & Korsinsky, LLP Files Complaint Against Anavex Life Sciences Corporation

Levi & Korsinsky, LLP Files Complaint Against Anavex Life Sciences Corporation

Anavex Life Sciences Corp. to Report Q1, 2024 Results on Feb 07, 2024

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia

Price target decreased by 26% to US$40.00

Anavex Life Sciences Corp. Announces First Entire Clinical Gene Pathway Data of Anavex®2-73 from Avatar Study in Patients with Rett Syndrome

Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease

New major risk - Revenue and earnings growth

Anavex Life Sciences Corp. to Report Fiscal Year 2023 Results on Nov 27, 2023

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency

Anavex Life Sciences Corp. Appoints David Goldberger as Senior Vice President Regulatory Affairs

Anavex Life Sciences Corp. Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX(R) 3-71 to Prevent Cognitive Decline in Alzheimer's Disease

New major risk - Revenue and earnings growth

Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Anavex Life Sciences Corp. Announces Phase 2b/3 Trial of Blarcamesine (ANAVEX 2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration

Anavex Life Sciences Reports Publication of ANAVEX®?3-71 in Clinical Journal Confirming ANAVEX®? 3-71 Clinical Cardiovascular Safety

Anavex Life Sciences Corp. to Report Q3, 2023 Results on Aug 08, 2023

Chairman notifies of intention to sell stock

Anavex Life Sciences Corp. Announces Long-Term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX(R)2-73 (blarcamesine) for Rett Syndrome

Anavex Life Sciences Corp.'s ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

Anavex Life Sciences Corp. Announces Completion of Anavex((R))2-73 (Blarcamesine) Excellence Phase 2/3 Rett Syndrome Clinical Trial

Forecast to breakeven in 2025

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Price target increased by 19% to US$47.00

Anavex Life Sciences Corp. Announces Exceeding of Enrollment Target for the ANAVEX(R)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Corp. to Report Q1, 2023 Results on Feb 07, 2023

Price target increased by 30% to US$41.67

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

Anavex Life Sciences Corp. Announces the Appointment of Timo Grimmer, Md, to Its Scientific Advisory Board

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Anavex Life Sciences Corp. to Report Q4, 2022 Results on Nov 28, 2022

Price target decreased to US$33.25

Insufficient new directors

Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2B/3 Data of Oral Anavex®2-73 (Blarcamesine) for Early Alzheimer’s Disease At the Upcoming Clinical Trials on Alzheimer’S Disease (Ctad) Congress 2022

Forecast to breakeven in 2025

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia

Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease

Anavex Life Sciences Corp. Reports New Publication in Medical Journal Highlighting the Relevance of Sigmar1 Activation to Compensate for Early Alzheimer's Disease

Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01

Anavex Life Sciences Corp. to Report Q3, 2022 Results on Aug 09, 2022

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Anavex: Increasing Shareholder Value Against All Odds

Independent Director exercised options and sold US$407k worth of stock

Anavex Life Sciences Corp. to Report Q2, 2022 Results on May 10, 2022

Price target decreased to US$31.00